

Jeff Landry
Governor
Edward J. Koehl, Jr.
Chairman
Mike R. McHalfey
1st Vice Chair
Earl A. "Boo" Landry, Jr.
2nd Vice Chair
Vincent V. Tumminello, Jr., M.D.
3rd Vice Chair



Commissioners
Dr. Patrick Bernard
Rock M. Bordelon
Leslie P. Bouie
Larry L. Findley, Sr., DVM
K. R. "Ron" Finkelstein, O.D.
Nathan C. Granger
Travis K. Miller, DVM
Deano Thomton
Katherine L. Winters
Stephen Landry
Executive Director

LOUISIANA STATE RACING COMMISSION

EMERGENCY MEETING NOTICE

THE LOUISIANA STATE RACING COMMISSION SHALL CONDUCT AN EMERGENCY PUBLIC MEETING AT 4:00 PM ON TUESDAY, JUNE 4, 2024. ALL INTERESTED PARTIES AND THE PUBLIC MAY PARTICIPATE IN THE MEETING ONLINE VIA ZOOM BY ENTERING MEETING ID 845 2478 5462 AND ENTERING PASSCODE 760089. ALL INTERESTED PARTIES AND THE PUBLIC MAY PARTICIPATE IN THE MEETING BY PHONE USING THE FOLLOWING NUMBERS THAT ARE CLOSEST TO THEIR PROXIMITY: (346) 248-7799 FOR HOUSTON, TX; (669) 900-6833 FOR SAN JOSE, CA; (929) 205-6099 FOR NEW YORK, NY; (253) 215-8782 FOR TACOMA, WA; (301) 715-8592 FOR WASHINGTON DC; (312) 626-6799 FOR CHICAGO, IL. ALL PHONE PARTICIPANTS MUST ENTER MEETING ID 845 2478 5462 AND ENTER PASSCODE 760089. PLEASE IDENTIFY YOURSELF AND REQUEST PERMISSION TO SPEAK BEFORE YOU COMMENT.

I. RULE

A. DISCUSSION:

1. LAC 35:I Chapter 17 – Corrupt and Prohibited Practices
§1725. Controlled Medication [amend]
 - Discussion of Clenbuterol
 - Discussion of Depo-Medrol
 - Safeguards will be in place during transition time for going back to increased withdrawal periods

II. ADJOURNMENT

A blue ink signature of Stephen Landry, consisting of stylized initials and a surname.

Stephen Landry
Executive Director

This notice was posted by the entrance of the Louisiana State Racing Commission, Monday, June 3, 2024 at 4:00PM.

**RULE FOR DISCUSSION
AT JUNE 4, 2024 EMERGENCY COMMISSION MEETING**

**Title 35
HORSE RACING
Part I. General Provisions**

Chapter 17. Corrupt and Prohibited Practices

§1725. Controlled Medication

A. Controlled medications are permitted in Louisiana as set forth in the ~~list of e~~Controlled Therapeutic mMedications Schedule for Horses – Version 4.1 as published by the Association of Racing Commissioners International, Inc. and shall only be administered as therein prescribed and regulated at the threshold levels set forth in said list, with the following exceptions:

1. The following medications may only be used intravenously on thoroughbreds at the specified dosages, either as one of the following medications administered at a withdrawal time of 24 hours at the specified dosages or as a combination of two of the following medications administered within 48 hours at a withdrawal time of 48 hours for the first medication and at a withdrawal time of 24 hours for the second medication at the specified dosages:

- a. phenylbutazone at a dosage of up to 2 grams;
- b. Banamine, or flunixin meglumine, at a dosage of up to 500 milligrams; and
- c. Ketofen, or ketoprofen, at a dosage of up to 1 gram.

2. The following medications may only be used one at a time intravenously on thoroughbreds and may not be used in combination at the specified withdrawal times and dosages:

- a. dexamethasone at a dosage of up to 20 milligrams with a withdrawal time of 48 hours; and
- b. triamcinolone at a dosage of up to 10 milligrams with a withdrawal time of 72 hours.

3. The following medications may only be used one at a time intra-articularly on thoroughbreds, or as joint injections, at a withdrawal time of 7 days at the specified dosages and may not be used in any combination at a withdrawal time of 7 days at the specified dosages:

- a. triamcinolone at a dosage of up to 20 milligrams;
- b. Depo-Medrol, or methylprednisolone acetate, at a dosage of up to 200 milligrams; and
- c. betamethasone at a dosage of up to 60 milligrams;

4. The following medications may only be used on thoroughbreds at the specified withdrawal times and dosages:

- a. dimethyl sulfoxide (DMSO), administered intravenously, at a dosage of up to 100 milliliters with a withdrawal time of 24 hours;
- b. methocarbamol at a dosage of up to 2 grams with a withdrawal time of 48 hours;

c. dantrolene at a dosage of up to 500 milligrams with a withdrawal time of 24 hours;

d. acepromazine, administered orally or intravenously, at a dosage of up to 50 milligrams with a withdrawal time of 48 hours;

e. xylazine at a dosage of up to 300 milligrams with a withdrawal time of 24 hours;

f. detomidine at a dosage of up to 10 milligrams with a withdrawal time of 24 hours;

g. Ventipulmin, or clenbuterol hydrochloride, at a dosage of up to 725 micrograms with a withdrawal time of 72 hours;

h. butorphanol at a dosage of up to 10 milligrams with a withdrawal time of 48 hours;

i. omeprazole with no withdrawal time;

j. calcium gluconate or calcium-magnesium-phosphorous-potassium-dextrose solution (CMPK) with no withdrawal time; and

k. acetylcysteine with no withdrawal time;

B. The eControlled tTherapeutic mMedications Schedule for Horses – Version 4.1 list as published by the Association of Racing Commissioners International, Inc., shall be maintained on the commission website and at the domicile office and be made available to the public upon request.

AUTHORITY NOTE: Promulgated in accordance with R.S. 4:148.

HISTORICAL NOTE: Adopted by the Racing Commission in 1971, promulgated by the Department of Commerce, Racing Commission, LR 2:449 (December 1976), amended LR 3:45 (January 1977), LR 4:287 (August 1978), amended by the Office of the Governor, Division of Administration, Racing Commission, LR 41:1672 (September 2015), LR

Louisiana State Racing Commission

Controlled Medication Schedule

LAC § 35:1725

Effective June 8, 2024

Controlled Medication	Threshold	Withdrawal Guideline	Dosage Specifications	Reference
Acepromazine (B, U)	0.02 ng/ml (B) 5.0 ng/ml (U)	48 hours	50 mg Oral or Intravenous	Kynch, et al., JVPT 41, 522-535, 2018
Acetylcysteine	No Threshold	No Withdrawal Time	n/a	Ch 17, § 1725
Betamethasone (B)	0.010 ng/ml	7 days	60 mg Intra-Articular	ARCI CMTS, 4.1
Butorphanol (B)	2.0 ng/ml	48 hours	10 mg	Kynch, et al., JVPT 36, 21-30, 2013
Calcium Gluconate or Calcium-Magnesium- Phosphorous- Potassium-Dextrose (CMPK)	No Threshold	No Withdrawal Time	n/a	Ch 17, § 1725
Clenbuterol (U, B)	3.0 ng/ml (U) 0.010 ng/ml (B)	72 hours	0.725 mg ¹ Oral or Intravenous	Soma, et al., JVPT 27, 71-77, 2004

Dantrolene (B)	5.0 ng/ml	24 hours	500 mg Oral	Kynch, et al., JVPT 34, 238, 2010
Detomidine (U, B)	5 ng/ml (U) 2.0 ng/ml (B) (as 3-hydroxy- detomidine)	24 hours	10 mg Intravenous	Paine, et al., JVPT, 2020; 43:162-170
Dexamethasone (B)	0.015 ng/ml	48 hours	20 mg Intravenous	Kynch, et al., DTA 12, 1087-1101, 2020
Dimethyl Sulfoxide (DMSO) (B)	100 ug/ml	24 hours	100 ml Intravenous	Soma, et al., JVPT 41, 384-392, 2018
Flunixin (B)	50 ng/ml 5.0 ng/ml	24 hours 48 hours	0.5 grams Intravenous	Kynch, et al., JVPT 38, 313-320, 2015 ARCI CMTS, 4.1
Ketoprofen (B)	3.0 ng/ml 2.0 ng/ml	24 hours 48 hours	1.0 gram Intravenous	Kynch, et al., DTA 16, 289-302, 2024 ARCI CMTS, 4.1
Methocarbamol (B)	5.0 ng/ml	48 hours	2 grams Oral or Intravenous	Kynch, et al., DTA 39, 469-477, 2016

Methylprednisolone (B)	2.0 ng/ml	7 days	200 mg Intra-Articular	Soma, et al., AJVR 67, 654, 2006
Omeprazole	No Threshold	No Withdrawal Time	n/a	Ch 17, § 1725
Phenylbutazone (B)	2.0 ug/ml 0.30 ug/ml	24 hours 48 hours	2 grams Intravenous	Kynch, et al., DTA 11, 792-803, 2019 ARCI CMTS, 4.1
Triamcinolone (B)	0.100 ng/ml 0.100 ng/ml	48 hours 7 days	10 mg Intravenous 20 mg Intra-Articular	Soma, et al., AJVR 72, 1234, 2011
Xylazine (B)	2 ng/ml	24 hours	300 mg Intravenous	ETRA, ManU071, AUS 2008

LEGEND: Urine (U) & Blood (B).

No adjustments should be made to the total dose permitted/administered to correct for weight of the horse unless it results in a lower dose. Routes of administrations other than those listed should not be performed as the thresholds and withdrawal times do not consider them.

¹This dose of Clenbuterol, even with a 72-hour withdrawal, should not be the last dose of a prior multi-day regimen of Clenbuterol, whether administered orally or intravenously.